RSV prevention in infants with nirsevimab and maternal vaccine
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and between 32 and 36 weeks along
- You are 18 years or older and able to read French or English
- You are willing to receive the RSV vaccine during pregnancy if assigned
- You are willing for your baby to receive nirsevimab after birth
- You are not pregnant with twins, triplets, or more
- You have not received any other RSV prevention product or taken part in another RSV trial during this pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two approved ways to prevent RSV, a common virus that can make babies very sick. Pregnant women may get a vaccine, and/or their babies may get an antibody shot after birth. The study compares these options to see which works best.
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
Hear when a new RSV Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.